DJIA 17,356.87 288.00 1.69%
NASDAQ 4,644.31 96.48 2.12%
S&P 500 2,012.89 40.15 2.04%
market minute promo

Gilead Sciences (NASDAQ: GILD)

102.40 1.94 (1.93%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

GILD $102.40 1.93%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $100.47
Previous Close $100.46
Daily Range $99.56 - $102.74
52-Week Range $63.50 - $116.83
Market Cap $154.5B
P/E Ratio 17.81
Dividend (Yield) $0.00 (0.0%)
Volume 13,548,853
Average Daily Volume 15,116,674
Current FY EPS $7.91





Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website:

News & Commentary

Pfizer, Inc. Invests in Growth... Literally

Pfizer, Inc. pays $275 million upfront for commercialization rights to Opko Health Inc.'s promising human growth hormone drug.

Noteworthy ETF Outflows: OEF, GILD, GOOG, PM

Gilead Sciences Stands Alone

Examining Gilead Sciences' Future Pipeline

The 3 Most Exceptional CEOs of 2014

These three CEOs delivered big gains for their shareholders in 2014. Find out what makes them so special.

How To Beat The Market - My Best Large-Cap Stock Portfolio: Gilead Sciences

Which Biotech Will Become the Next Gilead Sciences, Inc.?

Gilead Sciences' growth has been phenomenal over the past few years thanks to its hepatitis C and HIV infectious disease drugs. Find out which biotech could step into Gilead's high-growth shoes.

2015 Healthcare Sector Predictions

Druckenmiller Adds Healthcare Stocks to Portfolio

There Is Still Time To Join The Gilead Bandwagon

See More GILD News...

GILD's Top Competitors

GILD $102.40 (1.93%)
Current stock: GILD
AMGN $163.48 (2.53%)
Current stock: AMGN
CELG $112.82 (2.48%)
Current stock: CELG
$0.00 (0.00%)
Current stock: